CureMatch
6370 Lusk Boulevard
Suite F208
San Diego
California
92121
United States
Tel: 858-859-2873
Fax: 858-430-5813
Website: http://www.curematch.com/
Email: info@curematch.com
About CureMatch
CureMatch™ was founded because we identified the need for improved decision-support within the UCSD Tumor Board. Each of the founders has a personal drive to contribute to the field of Precision Medicine. Cancer has closely impacted each of us and we want to use our scientific, entrepreneurial and financial experience to contribute to the good of the community. We look forward to providing physicians with the means to improve cancer patients’ quality of life.YEAR FOUNDED:
2015
LEADERSHIP:
CEO and Chairman of the Board: Blaise Barrelet
Co-Founder and CTO: Igor Tsigelny, PhD
Co-Founder & Medical Advisor: Razelle Kurzrock, MD
President & COO: Stephane Richard, PhD
TECHNOLOGY:
Please click here for CureMatch's technology.
13 articles about CureMatch
-
Massive Bio and CureMatch Announce Groundbreaking Partnership to Revolutionize Cancer Treatment through AI and Clinical Trial Accessibility
7/18/2023
Massive Bio and CureMatch have joined forces in a transformative partnership aimed at revolutionizing cancer treatment.
-
CureMatch Hires CFO, CTO
6/26/2019
CureMatch is pleased to announce two new hires. Katie Breitenbach has joined the AI-driven oncology treatment analysis company as chief financial officer; Viktor Novy has joined as chief technical officer.
-
SOTERIA and CureMatch Partner to Support Oncologists with Personalized Cancer Treatment Options
4/26/2018
SOTERIA Precision Medicine Advisory, Inc. and CureMatch, Inc. have entered into an agreement to facilitate the delivery of Personalized Combination Therapy® options to the global cancer care community.
-
Co-Founder of CureMatch Precision Oncology Technology is Co-Author in Cancer Discovery Journal
1/26/2018
The current Cancer Discovery article highlights how liquid biopsy techniques, which apply genomic sequencing of circulating DNA isolated from a small vial of blood, can effectively detect cellular mutations in colorectal cancer patients.
-
CureMatch Co-Founders Study The Molecular Alterations Of Genes To Develop Personalized Cancer Therapy Options
9/8/2017
-
Serra Ventures Invests In CureMatch
8/16/2017
-
CureMatch Announces Pricing For Its Cutting-Edge Combination Therapy Report For Cancer Treatment
5/25/2017
-
CureMatch Partnering With Patient Power To Educate And Empower Patients And Oncologists Regarding Personalized Cancer Treatments
3/30/2017
-
CureMatch Launches Decision Support Platform To Harness The Power Of Personalized Medicine In Cancer Care
3/7/2017
-
CureMatch Launches Decision Support Platform To Harness The Power Of Personalized Medicine In Cancer Care
3/7/2017
-
CureMatch Announces New Advances In Using Metabolomic Profiling To Distinguish Among Cancer Subtypes
2/24/2017
-
Study Validates A Core Principle Behind The CureMatch Technology
2/17/2017
-
CureMatch Announces Publication In Oncoimmunology Of Data Unveiling A Specific Mutagenesis Process Linked To The Response To Immunotherapy In Cancer
2/7/2017